Salestools LogoSalestools
Salestools LogoSalestools
Biotech

CRISPR Therapeutics

CRISPR Therapeutics raises $337M Follow-on Offering at $8B valuation

$337M
Total Raised
Follow-on Offering
Latest Round
2013
Founded
500+
Employees
Aeschenvorstadt 36, Basel 4051, Switzerland
1 min read

Quick Facts

Valuation
$8B
Latest Round Size
$337M
Latest Round Date
September 2024

CRISPR Therapeutics: Follow-on Offering Funding Round

CRISPR Therapeutics has successfully raised $337M in Follow-on Offering funding, reaching a valuation of $8B.

Company Overview

Gene-based medicines using CRISPR/Cas9

Funding Details

The Follow-on Offering round was led by Versant Ventures, with participation from Bayer, Vertex Pharmaceuticals.

Company Information

  • Headquarters: Aeschenvorstadt 36, Basel 4051, Switzerland
  • Founded: 2013
  • Employees: 500+
  • Category: Biotech

Investment

CRISPR Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Versant Ventures: Verified investor in Follow-on Offering
  • Bayer: Verified investor in Follow-on Offering
  • Vertex Pharmaceuticals: Verified investor in Follow-on Offering

Key Investors

Versant Ventures
Lead Investor
Verified investor in Follow-on Offering
Bayer
Investor
Verified investor in Follow-on Offering
Vertex Pharmaceuticals
Investor
Verified investor in Follow-on Offering

Topics

verified(3079)real-funding(3079)crispr-therapeuticsbiotechfollow-on-offeringaeschenvorstadt-36

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M